First patient receives Oxford-AstraZeneca COVID-19 vaccine
Brian Pinker was the first person to receive AZD1222, the COVID-19 vaccine developed by the University of Oxford and AstraZeneca, this morning.
List view / Grid view
News
Optimised formulation of gentamicin could reduce hearing loss
Analysing the components of gentamicin, researchers have developed a new formulation for the antibiotic that does not cause deafness.
EC orders additional 80 million doses of Moderna’s COVID-19 vaccine
Europe will receive an extra 80 million doses of Moderna's mRNA-1273, a COVID-19 vaccine candidate, following the EC's decision.
Oral contraceptive pills protect against ovarian and endometrial cancer, study finds
A study has shown that the use of oral contraceptives gave women a much lower risk of developing both ovarian and endometrial cancer.
Phase III study to confirm efficacy of siltuximab as COVID-19 therapy initiated
The SILVAR study is designed to reaffirm the results of the SISCO trial, which showed that siltuximab led to a reduced mortality rate from COVID-19.
Oral hormone therapy found to alter metabolome of postmenopausal women
Research has shown oral hormone therapy significantly impacts the metabolome of postmenopausal women, explaining certain disease risks.
First hospitalised COVID-19 patient dosed in FSD201 treatment trial
The study will evaluate whether FSD201 is safe and of benefit to hospitalised patients with COVID-19, in combination with standard of care.
Phase I/II trial initiated to study VLA2001, potential COVID-19 vaccine
Valneva has initiated its Phase I/II trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Triple combination of therapies shows promise in pancreatic cancer trial
The combination of motixafortide, KEYTRUDA® and chemotherapy met all trial endpoints, including increasing overall and progression free survival.
Many people may not receive a COVID-19 vaccine until 2022
Studies show that more than a fifth of the global population, mostly in low- and middle-income countries, may have to wait until at least 2022 to receive a COVID-19 vaccine.
First patient enrolled in clinical trial of COVID-19 vaccine CVnCoV
The first participant has been enrolled in a Phase IIb/III study of CVnCoV, CureVac's mRNA COVID-19 vaccine candidate.
AstroRx® shows promise in early phase amyotrophic lateral sclerosis trial
Amyotrophic lateral sclerosis (ALS) patients treated with AstroRx® had a 45 percent reduction in their disease progression rate.
Abbott receives CE mark for COVID-19 IgG quantitative antibody blood test
The new quantitative SARS-CoV-2 IgG lab-based serology test developed by Abbott has been given the CE mark.
AbbVie initiates Phase I trial to study SARS-CoV-2 neutralising antibody
AbbVie has licensed the SARS-CoV-2 neutralising antibody, 47D11, from Harbour BioMed and Utrecht University and begun clinical trials.
Class 4 Medicines Defect: missing safety information in some Perindopril products
The MHRA reports that certain packs of Perindopril products are missing important safety information, the products are not being recalled.
